(2S,3S)-3-(2-aminophenylamino)-2-(tert-butoxycarbonylamino)butanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,3S)-3-(2-aminophenylamino)-2-(tert-butoxycarbonylamino)butanoic acid
• 英文别名: (2S,3S)-3-(2-amino-phenylamino)-2-tert-butoxycarbonylamino-butyric acid；(2S,3S)-3-(2-aminoanilino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid
• 化学式: C₁₅H₂₃N₃O₄
• 分子量: 309.365
• InChiKey: VETWWUJCPYMMPW-CABZTGNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  114
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2S,3S)-3-(2-aminophenylamino)-2-(tert-butoxycarbonylamino)butanoic acid 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以91%的产率得到((2S,3S)-2-methyl-4-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  2-OXO-2,3,4,5-TETRAHYDRO-1 H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER

  摘要：

  本文披露了化合物I式或其药用盐，其中W、Y、Z、R1、R2、R3、R4和R5如本文所述，并且使用所述化合物治疗癌症的方法。

  公开号：

  US20150225449A1
• 作为产物：
  描述：

  (2S,3S)-2-(tert-butoxycarbonylamino)-3-(2-nitrophenylamino)butanoic acid 在 氮气 、 钯 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以to give (2S,3S)-3-(2-amino-phenylamino)-2-tert-butoxycarbonylamino-butyric acid which的产率得到(2S,3S)-3-(2-aminophenylamino)-2-(tert-butoxycarbonylamino)butanoic acid
  参考文献：
  名称：

  2-oxo-2,3,4,5-tetrahydro-1 H-benzo[B]diazepines and their use in the treatment of cancer

  摘要：

  本发明涉及Formula I化合物或其药学上可接受的盐，其中W、Y、Z、R1、R2、R3、R4和R5如本文所述，并且本发明涉及使用所述化合物治疗癌症的方法。

  公开号：

  US09422331B2

文献信息

• Optimization of Benzodiazepinones as Selective Inhibitors of the X-Linked Inhibitor of Apoptosis Protein (XIAP) Second Baculovirus IAP Repeat (BIR2) Domain
  作者：Robert F. Kester、Andrew F. Donnell、Yan Lou、Stacy W. Remiszewski、Louis J. Lombardo、Shaoqing Chen、Nam T. Le、Jennifer Lo、John A. Moliterni、Xiaochun Han、J. Heather Hogg、Weiling Liang、Christophe Michoud、Kenneth C. Rupert、Steven Mischke、Kang Le、Martin Weisel、Cheryl A. Janson、Christine M. Lukacs、Adrian J. Fretland、Kyoungja Hong、Ann Polonskaia、Lin Gao、Shirley Li、Dave S. Solis、Doug Aguilar、Christine Tardell、Mark Dvorozniak、Shahid Tannu、Edmund C. Lee、Andy D. Schutt、Barry Goggin

  DOI：10.1021/jm400732v

  日期：2013.10.24

  The IAPs are key regulators of the apoptotic pathways and are commonly overexpressed in many cancer cells. IAPs contain one to three BIR domains that are crucial for their inhibitory function. The pro-survival properties of XIAP come from binding of the BIR domains to the proapoptotic caspases. The BIR3 domain of XIAP binds and inhibits caspase 9, while the BIR2 domain binds and inhibits the terminal caspases 3 and 7. While XIAP BIR3 inhibitors have previously been reported, they also inhibit cIAP1/2 and promote the release of TNF alpha, potentially limiting their therapeutic utility. This paper will focus on the optimization of selective XIAP BIR2 inhibitors leading to the discovery of highly potent benzodiazepinone 36 (IC50 = 45 nM), which has high levels of selectivity over XIAP BIR3 and cIAP1 BIR2/3 and shows efficacy in a xenograft pharmacodynamic model monitoring caspase activity while not promoting the release of TNF alpha in vitro.
• 2-OXO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2897972B1

  公开（公告）日：2016-11-30
• US9422331B2
  申请人：——

  公开号：US9422331B2

  公开（公告）日：2016-08-23
• [EN] 2-OXO-2,3,4,5-TETRAHYDRO-1 H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER<br/>[FR] 2-OXO-2,3,4,5-TÉTRAHYDRO-1 H-BENZO[B]DIAZÉPINES ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014044622A1

  公开（公告）日：2014-03-27

  Disclosed are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein W, Y, Z, R1, R2, R3, R4 and R5 are described herein, and methods of using said compounds in the treatment of cancer.
• 2-OXO-2,3,4,5-TETRAHYDRO-1 H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20150225449A1

  公开（公告）日：2015-08-13

  Disclosed are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein W, Y, Z, R1, R2, R3, R4 and R5 are described herein, and methods of using said compounds in the treatment of cancer.

  本文披露了化合物I式或其药用盐，其中W、Y、Z、R1、R2、R3、R4和R5如本文所述，并且使用所述化合物治疗癌症的方法。